Maspin influences response to doxorubicin by changing the tumor microenvironment organization

International Journal of Cancer

Volumn 134, Issue 12, 2014, Pages 2789-2797

  Triulzi, Tiziana ^a   Ratti, Manuela ^a   Tortoreto, Monica ^a   Ghirelli, Cristina ^a   Aiello, Piera ^a   Regondi, Viola ^a   Di Modica, Martina ^a   Cominetti, Denis ^a   Carcangiu, Maria L ^a   Moliterni, Angela ^a   Balsari, Andrea ^a,b   Casalini, Patrizia ^a   Tagliabue, Elda ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

drug delivery; extracellular matrix; maspin; response to doxorubicin

Indexed keywords

COLLAGEN FIBER; DOXORUBICIN; MASPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER REGRESSION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; EMBRYO; ENZYME ACTIVITY; ENZYME LOCALIZATION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

DRUG DELIVERY; EXTRACELLULAR MATRIX; MASPIN; RESPONSE TO DOXORUBICIN;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN; DISEASE PROGRESSION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; SERPINS; TUMOR MICROENVIRONMENT;

EID: 84898002937     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28608     Document Type: Article

References (40)

1. Tredan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99: 1441-1454.
2. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994; 263: 526-529.
3. Law RH, Irving JA, Buckle AM, et al. The high resolution crystal structure of the human tumor suppressor maspin reveals a novel conformational switch in the G-helix. J Biol Chem 2005; 280: 22356-22364.
4. Bernardo MM, Meng Y, Lockett J, et al. Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes Cancer 2011; 2: 1009-1022.
5. Hendrix MJ,. De-mystifying the mechanism(s) of maspin. Nat Med 2000; 6: 374-376.
6. Pemberton PA, Tipton AR, Pavloff N, et al. Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface. J Histochem Cytochem 1997; 45: 1697-1706.
7. Khalkhali-Ellis Z, Hendrix MJ,. Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation. Cancer Res 2007; 67: 3535-3539.
8. Khalkhali-Ellis Z,. Maspin: the new frontier. Clin Cancer Res 2006; 12: 7279-7283.
9. Ghedini GC, Ciravolo V, Tortoreto M, et al. Role of soluble HER2 extracellular domain in HER2-mediated tumor growth and in response to Trastuzumab. J Cell Physiol 2010; 225: 256-265.
10. Pupa SM, Forti S, Invernizzi AM, et al. Monoclonal antibody to fibulin-1 generated by genetic immunization. J Cell Biochem 2003; 89: 647-652.
11. Castiglioni F, Terenziani M, Carcangiu ML, et al. Radiation effects on development of HER2-positive breast carcinomas. Clin Cancer Res 2007; 13: 46-51.
12. Bergamaschi A, Hjortland GO, Triulzi T, et al. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 2009; 3: 469-482.
13. Vandesompele J, De PK, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
14. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-369.
15. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-5121.
16. Bergamaschi A, Tagliabue E, Sorlie T, et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 2008; 214: 357-367.
17. Simon R, Lam A, Li MC, et al. Analysis of gene expression data using BRB-array tools. Cancer Inform 2007; 3: 11-17.
18. Mosley JD, Keri RA,. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genomics 2008; 1: 11.
19. Seftor RE, Seftor EA, Sheng S, et al. Maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res 1998; 58: 5681-5685.
20. Sheng S, Carey J, Seftor EA, et al. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci U S A 1996; 93: 11669-11674.
21. Pupa SM, Ménard S, Forti S, et al. New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002; 192: 259-267.
22. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5: 662-668.
23. Helleman J, Jansen MP, Ruigrok-Ritstier K, et al. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 2008; 14: 5555-5564.
24. Hazlehurst LA, Dalton WS,. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev 2001; 20: 43-50.
25. Naci D, El Azreq MA, Chetoui N, et al. alpha2beta1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J Biol Chem 2012; 287: 17065-17076.
26. Solomon LA, Munkarah AR, Schimp VL, et al. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol 2006; 101: 385-389.
27. Goulet B, Kennette W, Ablack A, et al. Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. Lab Invest 2011; 91: 1181-1187.
28. Mohsin SK, Zhang M, Clark GM, et al. Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 2003; 199: 432-435.
29. Sood AK, Fletcher MS, Gruman LM, et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 2002; 8: 2924-2932.
30. Blacque OE, Worrall DM,. Evidence for a direct interaction between the tumor suppressor serpin, maspin, and types I and III collagen. J Biol Chem 2002; 277: 10783-10788.
31. Weaver VM, Lelievre S, Lakins JN, et al. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002; 2: 205-216.
32. Tannock IF, Lee CM, Tunggal JK, et al. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002; 8: 878-884.
33. Netti PA, Berk DA, Swartz MA, et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000; 60: 2497-2503.
34. Loeffler M, Kruger JA, Niethammer AG, et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006; 116: 1955-1962.
35. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461.
36. Sopel M, Kasprzyk I, Berdowska I,. Maspin and c-erbB-2 expression in correlation with microvessel density in invasive ductal breast cancer. Folia Histochem Cytobiol 2005; 43: 109-116.
37. Sharma G, Mirza S, Parshad R, et al. Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression. Tumour Biol 2011; 32: 23-32.
38. Stylianopoulos T, Martin JD, Chauhan VP, et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A 2012; 109: 15101-15108.
39. Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 418-429.
40. Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2012; 62: 112-120.